ACS diagnosis and risk stratification in US and Europe

Bharatbook added a new report on "Stakeholder Insight: Acute Coronary Syndromes - ACS management strategies in the US and Europe" into its market report catalogue for reselling

Online PR News – 15-May-2010 – – Stakeholder Insight: Acute Coronary Syndromes - ACS management strategies in the US and Europe

ACS are manifestations of coronary heart disease, a leading cause of death in the developed world. Treatment is centered on restoring myocardial blood supply; reperfusion strategy is informed by ACS diagnosis and risk stratification, and in turn drives pharmaceutical choices. Uncertainty about risk calculation and best practice in ACS leads to variations in therapy use across the major markets.( )

*Analysis of current ACS management practices in the five major EU markets and US, and comparison with treatment guidelines and historical trends.
*Examination of the ACS patient population, age and sex correlations and co-morbidities across ACS diagnoses.
*Analysis of reperfusion in ACS: risk stratification and the choice of PCI, thrombolysis or conservative treatment without reperfusion.
*Overview of pharmaceutical therapies in ACS, including anti-ischemic, antiplatelet and anticoagulant classes.


The predominant admission route for all types of patient is via an emergency room (ER), either independently or by ambulance. France shows the highest rate of presentation direct to the catheterization lab while Spain and the US show lower use of ambulance transport.
ACS diagnosis determines reperfusion strategy. PCI dominates thrombolysis in STEMI patients, while in UA/NSTEMI just under half of patients undergo PCI while the remainder are treated conservatively. Overall some ACS patients are left unreperfused who would likely benefit from more aggressive treatment.
Reperfusion strategy drives further patient management. ADP antagonists are the dominant antiplatelet therapy in PCI while GPIIb/IIIa inhibitors play a lesser role and aspirin is highly used across ACS diagnoses. The heparins, UFH and enoxaparin, continue to dominate anticoagulant choice in PCI and non-PCI patients, respectively.
Reasons to Purchase

*Understand current patient populations, diagnostic methods and treatment approaches in ACS
*Quantify current use of pharmaceutical therapies and reperfusion therapies, such as PCI and thrombolysis
*Unveil the in-depth influencing factors leading to selection of specific strategies, and compare practice in the five major EU markets and the US
To know more and to buy a copy of your report feel free to visit :


Contact us at :

Bharat Book Bureau
Tel: +91 22 27578668
Fax: +91 22 27579131
Follow us on twitter: